From Adam Feuerstein from TheStreet:
“Gilead Sciences should solve the long-term revenue cliff problem some investors and analysts believe the company faces by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Writing to clients Tuesday morning, Porges says Gilead “needs the promise or high probability of an incremental $5-7 billion of revenue to reassure investors about their future outlook, and ideally any investment would add optionality for even higher revenue should upside scenarios play out.”
Well, what do you think? Full article